AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $33.63.

Several research analysts have recently issued reports on the company. Johnson Rice reissued a “buy” rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a research report on Wednesday, February 12th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. Wells Fargo & Company boosted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, HC Wainwright restated a “neutral” rating and issued a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC increased its holdings in AnaptysBio by 9,778.9% in the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company’s stock worth $35,000 after buying an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of AnaptysBio in the fourth quarter worth approximately $40,000. AlphaQuest LLC raised its holdings in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 4,237 shares during the last quarter. Finally, Virtus ETF Advisers LLC lifted its position in AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 936 shares during the period.

AnaptysBio Stock Up 1.3 %

NASDAQ:ANAB opened at $18.10 on Wednesday. The firm’s fifty day simple moving average is $17.39 and its 200 day simple moving average is $20.27. The stock has a market cap of $555.07 million, a P/E ratio of -2.98 and a beta of -0.09. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $43.11 million for the quarter, compared to analysts’ expectations of $10.17 million. On average, analysts expect that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has approved a share buyback program on Monday, March 24th that allows the company to repurchase $75.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.